Session » Poster Session 2

The 2020 Pediatric Rheumatology Symposium, originally scheduled for April 29 – May 2, was postponed due to COVID-19; therefore, abstracts were not presented as scheduled.

Date: Friday, May 1, 2020

Time: 5:00PM-6:00PM

Meeting: 2020 Pediatric Rheumatology Symposium

5:00PM-6:00PM: Abstract Number: 094

A Good Inter- and Intra-observer Reliability of Subtypes in Nailfold Capillary Micro-haemorrhages in Childhood-onset Systemic Lupus Erythematosus

5:00PM-6:00PM: Abstract Number: 108

A Multinational Study of Thrombotic Microangiopathy in Macrophage Activation Syndrome: A Dreadful Condition Which Is Likely Underrecognized

5:00PM-6:00PM: Abstract Number: 097

A Pilot Randomized Controlled Trial of the iCanCope Pain Self-management Application for Adolescents with Juvenile Idiopathic Arthritis

5:00PM-6:00PM: Abstract Number: 086

Advanced Multidisciplinary Care: A New Approach to Childhood Arthritis

5:00PM-6:00PM: Abstract Number: 082

Anti-Mitochondrial Autoantibodies Are Associated with Dysphagia in Juvenile and Adult Myositis, and with Persistent Weakness and Cardiomyopathy in Adult Myositis

5:00PM-6:00PM: Abstract Number: 175

Application of Juvenile Idiopathic Arthritis Treatment Guidelines and Factors Associated with Increased Likelihood of Intra-articular Corticosteroid Administration

5:00PM-6:00PM: Abstract Number: 089

Associations Among Pain, Mood, and Sleep in Children with Rheumatic Conditions

5:00PM-6:00PM: Abstract Number: 106

Childhood-onset Takayasu Arteritis: A Single Center Case Series of Atypical and Varied Presentations

5:00PM-6:00PM: Abstract Number: 157

Chondrocytes Influence Fibroblast-like Synoviocytes from Patients with Juvenile Idiopathic Arthritis, Through the Abrogation of BMP Signaling, to Delay Cell Differentiation and Maturation

5:00PM-6:00PM: Abstract Number: 110

Consequences and Predictors of Persisting Pain in Children with Juvenile Idiopathic Arthritis: A Case Control Study Nested in the ReACCh-Out Cohort

5:00PM-6:00PM: Abstract Number: 107

Defining the Prevalence of Depression and Anxiety Symptoms in Adolescents with Juvenile Idiopathic Arthritis

5:00PM-6:00PM: Abstract Number: 105

Discovering the Implications of Adiposity in Juvenile Dermatomyositis

5:00PM-6:00PM: Abstract Number: 100

Does Anakinra Dampen Neuronal Damage in Children with Febrile-Infection Related Epilepsy Syndrome (FIRES): A Single Center Review of Neuroimaging

5:00PM-6:00PM: Abstract Number: 098

Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis

5:00PM-6:00PM: Abstract Number: 177

Educational Outcomes in a Young-Adult Cohort of Patients with Childhood Onset Systemic Lupus Erythematosus (SLE)

5:00PM-6:00PM: Abstract Number: 158

Genetics of Age at Diagnosis in Childhood-Onset Systemic Lupus Erythematosus

5:00PM-6:00PM: Abstract Number: 178

HEADSS and Shoulders, Knees and Toes: Improving Sexual Orientation and Gender Identity Screening in the Pediatric Rheumatology Clinic

5:00PM-6:00PM: Abstract Number: 176

Implementation of an Abbreviated Neuropsychology Screening Protocol for Patients Diagnosed with Childhood-onset Systemic Lupus Erythematosus

5:00PM-6:00PM: Abstract Number: 102

Implications of Positive Tests for ANCA in a Pediatric Population

5:00PM-6:00PM: Abstract Number: 174

Improving Hospital Discharge Instructions for Pediatric Rheumatology Patients

5:00PM-6:00PM: Abstract Number: 109

Incidence, Contributing Factors, and Impact of Diagnostic Delay in Juvenile Idiopathic Arthritis: Analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry

5:00PM-6:00PM: Abstract Number: 084

Kawasaki Disease Shock Syndrome: A Single Center Cohort

5:00PM-6:00PM: Abstract Number: 096

Medication Adherence in Adolescents and Young Adults with Childhood Onset SLE

5:00PM-6:00PM: Abstract Number: 156

Metabolic Profiling in Juvenile Dermatomyositis

5:00PM-6:00PM: Abstract Number: 104

Patients Perspectives on Living with a Systemic Autoinflammatory Disease: Impact on Quality of Life

5:00PM-6:00PM: Abstract Number: 155

Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) Is Characterized by a Novel Subset of Monocytes with Markers Associated with Crossing the Blood Brain Barrier (BBB)

5:00PM-6:00PM: Abstract Number: 091

Protracted Febrile Myalgia Findings on Magnetic Resonance Imaging

5:00PM-6:00PM: Abstract Number: 095

Pyoderma Gangrenosum Ulceration as a Presenting Feature of Pediatric Granulomatosis with Polyangiitis (GPA)

5:00PM-6:00PM: Abstract Number: 078

Reliability and Validity of a New Skin Activity Measure for Localized Scleroderma

5:00PM-6:00PM: Abstract Number: 099

Reversible Hepatotoxicity to IL-1/IL-6 Blockade in Pediatric Patients with Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome

5:00PM-6:00PM: Abstract Number: 081

Risk Score of Macrophage Activation Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis

5:00PM-6:00PM: Abstract Number: 087

Standardizing Care and Fostering Systemic Autoinflammatory Disease (SAID) Research Through the CARRA Autoinflammatory Disease Network

5:00PM-6:00PM: Abstract Number: 088

Sun Protection Use in Patients Followed in a Pediatric Rheumatology Clinic in an Urban Setting

5:00PM-6:00PM: Abstract Number: 154

T Helper Cell Differentiation in Polyarticular Juvenile Idiopathic Arthritis

5:00PM-6:00PM: Abstract Number: 092

The Initial Treatment of Systemic Juvenile Idiopathic Arthritis: An International Collaboration Among 10 Registries

5:00PM-6:00PM: Abstract Number: 080

Therapeutic Interferon Gamma Neutralization with Emapalumab in Patients with NRLC4- and CDC42-Associated Diseases Characterized by Recurrent and Severe Hemophagocytic Lymphohistiocytosis

5:00PM-6:00PM: Abstract Number: 079

Traditional Laboratory Parameters and New Biomarkers in Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis

5:00PM-6:00PM: Abstract Number: 093

Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry

5:00PM-6:00PM: Abstract Number: 077

Tubulointerstitial Nephritis and Uveitis (TINU): A Pediatric Case Series with Longitudinal Followup

5:00PM-6:00PM: Abstract Number: 103

Unexpectedly High Incidence of Kawasaki Disease in a Well-Characterized Population in Atlantic Canada

5:00PM-6:00PM: Abstract Number: 090

Using a Patient-Engaged Approach to Identify Cross-Cutting Disease Factors Impacting Mental Health in Youth with Rheumatologic Disease

5:00PM-6:00PM: Abstract Number: 101

Uveitis Treatment in the CARRA II Registry: Tumor Necrosis Factor-inhibitors and Beyond

5:00PM-6:00PM: Abstract Number: 085

Vitamin C Deficiency: An Under-Recognized Cause for Pediatric Limb Pain

5:00PM-6:00PM: Abstract Number: 111

WITHDRAWN

5:00PM-6:00PM: Abstract Number: 112

WITHDRAWN

5:00PM-6:00PM: Abstract Number: 083

Worsening Disease Activity and Inability to Taper Corticosteroids in an Ethnically Diverse Cohort of Pediatric-Onset Lupus Patients After Transition to Adult Care

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].